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Abstract
Background Skeletal muscle depletion or sarcopenia is related to multiple adverse clinical outcome. However, frailty ques-
tionnaires are currently applied in the daily practice to identify patients who are potentially (un)suitable for treatment but are
time consuming and straining for patients and the clinician. Screening for sarcopenia in patients with head and neck cancer
(HNC) could be a promising fast biomarker for frailty. Our objective was to quantify sarcopenia with pre-treatment low skeletal
muscle mass from routinely obtained neck computed tomography scans at level of third cervical vertebra in patients diag-
nosed with HNC and evaluate its association with frailty.
Methods A total of 112 HNC patients with Stages III and IV disease were included from a prospective databiobank. The
amount of skeletal muscle mass was retrospectively deﬁned using the skeletal muscle index (SMI). Correlation analysis be-
tween SMI and continuous frailty data and the observer agreement were analysed with Pearson’s r correlation coefﬁcients.
Sarcopenia was present when SMI felt below previously published non-gender speciﬁc thresholds (<43.2 cm2/m2). Frailty
was evaluated by Geriatrics 8 (G8), Groningen Frailty Indicator, Timed Up and Go test, and Malnutrition Universal Screening
Tool. A univariate and multivariate logistic regression analysis was performed for all patients and men separately to obtain
odds ratios (ORs) and 95% conﬁdence intervals (95% CIs).
Results The cohort included 82 men (73%) and 30 women (27%), with a total mean age of 63 (±9) years. The observer
agreement for cross-sectional measurements was excellent for both intra-observer variability (r = 0.99, P < 0.001) and
inter-observer variability (r = 0.98, P < 0.001). SMI correlated best with G8 frailty score (r = 0.38, P < 0.001) and did not differ
per gender. Sarcopenia was present in 54 (48%) patients, whereof 25 (46%) men and 29 (54%) women. Prevalence of
frailty was between 5% and 54% depending on the used screening tool. The multivariate regression analysis for all patients
and men separately isolated the G8 questionnaire as the only independent variable associated with sarcopenia (OR 0.76,
95% CI 0.66–0.89, P < 0.001 and OR 0.76, 95% CI 0.66–0.88, P < 0.001, respectively).
Conclusions This is the ﬁrst study that demonstrates that sarcopenia is independently associated with frailty based on the
G8 questionnaire in HNC patients. These results suggest that in the future, screening for sarcopenia on routinely obtained neck
computed tomography scans may replace time consuming frailty questionnaires and help to select the (un)suitable patients
for therapy, which is highly clinically relevant.
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Introduction
Head and neck cancer (HNC) represents worldwide an impor-
tant population burden, with annually more than 550 000
new cases and 380 000 deaths.1 Moreover, incidence in the
Netherlands of patients with HNC has increased from 2077
in 1990 to 3081 in 2017 and will most likely continue to in-
crease due to aging of our society.2 Approximately two-thirds
of patients with HNC are diagnosed with advanced disease
and require complex treatment, including surgery, radiother-
apy, and systemic therapy (chemotherapy and/or immuno-
therapy) in a multidisciplinary approach.3 Despite
progression in treatment in the last decade, treatment is
not always successful with an overall 5-year survival of 40–
50%4,5 and is generally straining resulting in adverse events
including toxicity, complication, and mortality.6 In addition,
HNC patients are a challenging population with signiﬁcant
pre-existent health problems that could interfere with their
treatment plan,7 including an increased risk of malnutrition
due to dysphagia and changes of metabolism induced by
the tumour.8 It is therefore of great importance to identify
which patients are (un)suitable for treatment.
Currently, the comprehensive geriatric assessment (CGA) is
considered as a gold standard to diagnose frailty, which is as-
sociated with poor outcomes and higher risks of treatment;
therefore, it assesses the biological age, rather than the
chronological age per se to identify for treatment (un)suitable
patients.9,10 A CGA is a multidimensional and interdisciplinary
assessment through evaluating physical, psychological,
functional, and social capabilities and limitations of the
onco-geriatric patient.10 Although CGA is the most valid and
reliable method, it is very time intensive. Alternatively, frailty
questionnaires are used to identify patients who should un-
dergo a full CGA,11 which are also time intensive even though
it is a shorter procedure. Moreover, questionnaires suffer
from subjectivity. A biological marker of frailty would be more
accurate, but such a marker does not yet exist. There are
several promising studies, but no breakthrough has been
achieved on this ﬁeld of research, for example, elevated IL-6
and adiponectin level12 and pattern of circulating amino acid
levels.13 As a consequence, there is a search for a fast bio-
marker to identify frail patients.
Screening for sarcopenia could be such an alternative.
Sarcopenia is deﬁned by European Working Group on
Sarcopenia in Older People as a progressive and generalized
skeletal muscle disorder that is associated with increased like-
lihood of adverse outcomes including falls, fractures, physical
disability, and mortality.14 Sarcopenia is conﬁrmed by the
presence of low skeletal muscle mass.14 Muscle quantity is
classically measured on abdominal computed tomography
(CT) at level of third lumbar vertebra (L3) because of the ac-
curacy and strong correlation of the single slice measurement
with the total body skeletal muscle mass15,16 and the avail-
ability of routinely made abdominal CT scans in abdominal
oncology patients.17 Recent developments make it possible
to assess skeletal muscle mass at the level of C3 using neck
CT scans, which are nowadays a part of the normal diagnostic
work-up in HNC patients.18 This is a major leap in assessing
sarcopenia in HNC patients, as most HNC patients (93%) lack
abdominal imaging with CT.19 Importantly, sarcopenia is re-
lated to adverse clinical outcomes including disability, malnu-
trition, poor response to chemotherapy with increased
toxicity, post-operative complications, and lower overall sur-
vival in abdominal oncology populations.17,20,21 Associations
of sarcopenia and frailty in HNC patients remain unexplored
till now. Assessing skeletal muscle mass with neck CT scans
might be a promising, feasible, cost-effective, innovative,
and fast imaging biomarker to assess adverse outcome in-
cluding frailty in HNC patients.
Before widespread clinical implementation of CT measured
skeletal muscle mass at C3 is possible, it is important to
understand the interaction of skeletal muscle mass with dif-
ferent domains of frailty in HNC patients. The primary aim
of this present study is to quantify pre-treatment C3 skeletal
muscle mass in patients diagnosed with HNC and analyse its
association with frailty. Our secondary aim was to investigate
whether C3 low skeletal muscle mass, or sarcopenia, is re-
lated to mobility and nutritional status.
Methods
Patients and study design
Patients diagnosed between November 2014 and September
2017 with squamous cell carcinoma of the oral cavity, larynx,
oropharynx, and hypopharynx with Stages III and IV disease
(according to the 7th edition AJCC staging manual) were
included (n = 163). To prevent possible pathophysiological in-
terference, patients with a history of malignancies or patients
with multiple simultaneous primary malignant tumours were
excluded from the here presented analyses (n = 26). Patients
without neck CT scan at time of diagnosis were also excluded
(n = 17). This resulted in an initial inclusion of 121 patients.
Image analysis was not possible due to various image analysis
implications in ﬁve patients: a too small ﬁeld of view (n = 3), a
skewed CT image of the neck (n = 1), and an analysis error
due to incompatibility of extern origin CT images (n = 1). An
additional four patients were excluded from the cohort anal-
ysis because one or both sternocleidomastoid muscles were
inﬁltrated by lymphatic node metastasis, which are used for
skeletal muscle quantiﬁcation, and discrimination between
metastasis and muscle was therefore not feasible. This re-
sulted in the ﬁnal inclusion of 112 patients (Figure 1).
The following baseline characteristics were retrieved from
a prospectively maintained databiobank and analysed retro-
spectively: age, gender, length, weight, body mass index
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(BMI), Adult Comorbidity Evaluation-27 index (ACE-27), alco-
hol abuse (men >3 units per day and women >2 units per
day),22 history of smoking, tumour site, and tumour stage.
Screening tools for frailty, mobility, and risk of
malnutrition.
An overview of all applied screening tools and cut-off values
can be found in Table 1. Frailty status was determined with
GFI and G8. The G8 frailty questionnaire is especially designed
for onco-geriatric patients, with seven items derived from
the Mini Nutritional Assessment and one item relative to pa-
tients age.23 GFI is a 15-item questionnaire to evaluate frailty
status in geriatrics through loss of function and resources in
physical, social, and psychological domains.24 Patients were
categorized as non-frail (GFI < 4 and G8 > 14) and frail
(GFI ≥ 4 and G8 ≤ 14).23,24
Timed Up and Go test (TUG) was performed to assess mo-
bility. During this test, the patient was asked to stand up from
a chair, walk 3 m, turn around, return to the chair, and sit
down.25 The risk on malnutrition was evaluated with the
ﬁve-step Malnutrition Universal Screening Tool (MUST). Out-
come of the MUST questionnaire depended on present BMI,
recent unplanned weight loss, and acute disease effect on nu-
tritional intake.26
Measurements to deﬁne skeletal muscle mass
All analysed CT scans of the neck were made in the normal diag-
nostic work-up before initiating treatment. CT scans were per-
formed preferable post-contrast, reconstructed with a 1 mm
slice thickness, and usage of a soft-tissue kernel. Image analysis
was conducted with Aquarius workstation iNtuition edition pro-
gram (ver.4.4.13.P3, Terarecon Inc., Foster City, CA, USA).
Quantiﬁcation of pre-treatment skeletal muscle mass was
determined for each patient according to the method previ-
ously published by Swartz et al.18 In short, C3 was used as a
landmark, and the foremost caudal CT slice in axial plane with
the entire vertebral arc displaying was selected. Angulation
for optimizing visibility was prohibited to ensure reproducibil-
ity. Threshold for Hounsﬁeld units (HU) were set from
29 HU to +150 HU, which corresponds with skeletal muscle
density.16 Most of the skeletal muscle was selected automat-
ically, while other densities such as bone structures and fat
inﬁltration were excluded. However, the outer counters had
to be manually adjusted for each region of interest to exclude
Figure 1 Flowchart of included and excluded patients. CT, computed tomography; OncoLifeS, Oncological Life Study; SCMM, Sternocleidomastoid
muscle.
Table 1 Domains and corresponding screening tools with applied cut-off values15,19–22
Tests used Outcome Cut-off value
Sarcopenia CSA at C3 SMI in cm2/m2 Sarcopenic = SMI <43.2
Frailty G8 Score ranged 0–17 Frail = G8 ≤14
GFI Score ranged 0–5 Frail = GFI ≥4
Malnutrition risk MUST Score ranged 0–6 Low risk = MUST = 0
Medium risk = MUST = 1
High risk = MUST ≥2
Mobility TUG Mean of two attempts in seconds Limited = TUG ≥20
C3, third cervical vertebrae; CSA, cross-sectional area; G8, Geriatrics 8; GFI, Groningen Frailty Indicator; MUST, Malnutrition Universal
Screening Tool; SMI, skeletal muscle index; TUG, Timed Up and Go test.
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for instance large veins (Figure 2). The right
sternocleidomastoid muscle, left sternocleidomastoid mus-
cle, and paravertebral muscles were separately contoured.
The total cross-sectional area (CSA, cm2) of the skeletal mus-
cle at C3 corresponds with the total sum of pixels within the
HU ranged from 29 to +150 of these three structures.
Thereafter, calculations were made to estimate the CSA at
L3 using the algorithm described by Swartz et al.[18] and was
furthermore adjusted for patients height (m2) resulting in
SMI (cm2/m2) (see legend of Figure 2). Sarcopenia, or low
skeletal muscle mass, was based on a research of Wendrich
et al.27 with a non-gender speciﬁc SMI cut-off point of
<43.2 cm2/m2 (P < 0.001), which is best associated with
the presence of chemotherapy dose-limiting toxicity in HNC
patients (lowest log-likelihood value).27
The main observer (A. T. Z.) performed skeletal muscle
analysis in all 112 patients. To evaluate inter-observer and
intra-observer reliability, 25 patients were randomly selected
and measured again by the main observer and another ob-
server (A. H.).
Statistical analysis
Firstly, the patient cohort was described regarding the base-
line. Continuous variables were presented as median and
interquartile range or mean and standard deviation, for re-
spectively non-normal and normal distributed data. Normal-
ity was tested using Kolmogorov–Smirnov analysis. Ordinal
or nominal variables were presented as absolute numbers
and percentage of total. The outcome, or skeletal muscle
mass status, was presented continuously based on SMI and
dichotomously as sarcopenic and non-sarcopenic based on
previously published non-gender speciﬁc cut-offs for SMI.27
To evaluate correlations of CSA measurements at C3 level
between right sternocleidomastoid muscle, left
sternocleidomastoid muscle, and paravertebral muscles,
inter-observer and intra-observer analyses were performed
with bivariate Pearson’s r correlation coefﬁcients. Correlation
between SMI and other continuous variables of frailty
screening tools were also analysed with bivariate Pearson’s
r correlation coefﬁcients. To evaluate whether frailty, im-
paired mobility, and risk of malnutrition are related to the
skeletal muscle status of a patient, univariate logistic regres-
sion analyses were performed, with sarcopenia as dependent
variable and the baseline variables as independent variables.
In this way, odds ratios (ORs) and 95% CIs were provided.
Variables that were statistically signiﬁcant (α < 0.05) in the
univariate regression (maximum 5)28 were included in the
multivariate logistic regression in a backward manner. As
gender was excluded to the multivariate regression analyses,
we performed additional analysis with data stratiﬁed for gen-
der and sarcopenia as dependent variable. Possible
multicollinearity was analysed with variance inﬂation factors.
SPSS version 23.0 (SPSS Inc., Chicago, IL, USA) was used for
all statistical analysis.
Results
General patient and disease characteristics
This retrospective cohort study (on prospectively gathered
data) incorporated 112 patients diagnosed with primary squa-
mous cell carcinoma of the head and neck between November
2014 and September 2017. Pre-treatment neck CT scans were
analysed. A summary of general characteristics is presented in
Table 2 and outcome of screening tools in Table 3. Most
patients had oropharyngeal cancer (49%), followed by laryn-
geal (24%), oral (18%), and hypo-pharyngeal (9%) cancer.
Three-quarters of patients had Stage IV advanced disease.
The majority of the patient sample was male (73%), and the
mean age at time of diagnosis was 63 (±9) years.
Prevalence of frail patients was 54% and 31% based on the
G8 (≤14) and GFI (≥4) questionnaire, respectively. Median
Figure 2 Example of skeletal muscle measurements on an axial CT slice at
level of C3. Circumvented right sternocleidomastoid muscle (A), left
sternocleidomastoid muscle (B), and paravertebral muscles (C) are shown
at the level of C3. Tissue with corresponding muscle HU values are pre-
sented in green. Tissues presented as black or white are not correspond-
ing with muscle HU values and are not included in the calculation when
circumvented. Total CSA of skeletal muscle at L3 is calculated according
to the algorithm given by Schwartz et al.18 Total CSA of skeletal muscle
at L3 (cm
2
) = 27.304 + 1.363*total CSA of skeletal muscle at C3
(cm2)  0.671*Age (years) + 0.640*Weight (kg) + 26.442*Sex (1 for fe-
male and 2 for male). SMI (cm2/m2) = CSA of skeletal muscle at L3
(cm2)/Length (m2). C3, third cervical vertebra; CSA, cross-sectional area;
CT, computed tomography; HU, Hounsﬁeld units; L3, third lumbar
vertebra.
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TUG time was 8 s, and ﬁve patients (5%) were classiﬁed as
having an impaired mobility (TUG ≥20 s). Based on MUST,
29% of patients had a high risk of malnutrition.
Quantiﬁcation of pre-treatment skeletal muscle
mass
Overall, mean SMI was 44.1 cm2/m2 (±8.1) in 112 patients and
ranged between 27.1 and 65.1 cm2/m2. When applying the
SMI cut-off point of <43.2 cm2/m2 by Wendrich et al.,27
48% (n = 54) patients were classiﬁed as sarcopenic. Sarcopenia
was present in 31% (n = 25) men and in 97% (n = 29) women.
Solely one woman was classiﬁed as non-sarcopenic.
Preferences for CT scan parameters were predominantly
achieved in 112 CT scans: 73% (n = 82) had a ≤1 mm slice
thickness, 94% (n = 106) was contrast enhanced, and 100%
had a soft-tissue kernel. If a slice thickness of 1 mm was
not available, a 2 mm thickness was used as best alternative.
In merely four cases, a deviating slice thickness was used,
namely, 1.25 (n = 1), 1.5 (n = 2), and 2.5 (n = 1). The mean
time between ﬁrst consultation and the CT scan was 1.6
(±2.4) weeks.
Table 2 Demographic and clinical characteristics in patients with and without sarcopenia
Total (n = 112) Non-sarcopenic (n = 58) Sarcopenic (n = 54) OR (95% CI) P value
Gender
Male 82 (73.2%) 57 (98.3%) 25 (46.3%) 1
Female 30 (26.8%) 1 (1.7%) 29 (53.7%) 66.1 (8.5–512.7) <0.001
Age (years) 63.2 (±9.2) 61.9 (±8.9) 64.5 (±9.4) 1.0 (1.0–1.1) 0.13
BMI (kg/m2) 23.4 (22.4–28.5) 26.7 (24.1–30.0) 23.0 (19.8–24.8) 0.8 (0.7–0.9) <0.001
ACE-27
0–1 69 (61.6%) 38 (65.5%) 31 (57.4%) 1
2–3 43 (38.4%) 20 (34.5%) 23 (42.6%) 1.4 (0.7–3.0) 0.38
Smoking
Never 9 (8.0%) 6 (10.3%) 3 (5.6%) 1
Active/Quit 103 (82.0%) 52 (89.7%) 51 (94.4%) 1.96 (0.5–8.3) 0.35
Alcohol abuse
No 78 (75.0%) 42 (75.0%) 36 (75.0%) 1
Yes 26 (25.0%) 15 (25.0%) 12 (25.0%) 1.0 (0.4–2.4) 1.00
Missing 8 2 6
Cancer site
Oral cavity 20 (17.9%) 10 (17.2%) 10 (18.5%) 1 0.36a
Oropharynx 55 (49.1%) 25 (43.1%) 30 (55.6%) 1.2 (0.4–3.3) 0.73
Hypopharynx 10 (8.9%) 5 (8.6%) 5 (9.3%) 1.0 (0.2–4.6) 1.00
Larynx 27 (24.1%0 18 (31.0%) 9 (16.7%) 0.5 (0.2–1.6) 0.25
Cancer stage
III 28 (25.0%) 14 (24.1%) 14 (25.9%) 1
IV 84 (75.0%) 44 (75.9%) 40 (74.1%) 0.9 (0.4–2.1) 0.83
ACE-27, Adult Comorbidity Evaluation-27 index; BMI, body mass index; C3, third cervical vertebra; CI, conﬁdence interval; CSA, cross-sec-
tional area; OR, odds ratio.
A univariate logistic regression with sarcopenia as dependent variable (n = 112). Normal distributed data are presented with mean (SD)
and non-normal distributed data with median (interquartile range). Underscored P values are signiﬁcant (α < 0.05).
aOverall P value of variable.
Table 3 Characteristics of screening tools in patients with and without sarcopenia
Total (n = 112) Non-sarcopenic (n = 58) Sarcopenic (n = 54) OR (95% CI) P value
GFI
Score 2.0 (1.0–4.0) 1.5 (1.0–3.8) 3.0 (1.0–5.0) 1.2 (1.0–1.4) 0.026
Missing 2 2 0
G8
Score 14.0 (11.0–16.0) 15.0 (12.8–16.0) 12.0 (10.0–15.3) 0.8 (0.7–0.9) <0.001
TUG
Score (s) 8.3 (7.0–10.4) 8.0 (6.9–10.0) 9.5 (7.3–12.5) 1.0 (1.0–1.1) 0.44
Missing 4 1 3
MUST
Low 59 (52.7%) 39 (67.2%) 20 (37.0%) 1 0.007a
Medium 21 (18.8%) 8 (13.8%) 13 (24.1%) 3.2 (1.1–8.9) 0.029
High 32 (28.6%) 11 (19.0%) 21 (38.9%) 3.7 (1.5–9.2) 0.005
G8, Geriatrics 8; GFI, Groningen Frailty Index; MUST, Malnutrition Universal Screening Tool; TUG, Timed Up and Go test.
A univariate logistic regression analysis with sarcopenia as dependent variable (n = 112). The non-normal distributed data are presented
with median (interquartile range). Underscored P values are signiﬁcant (α < 0.05).
aOverall P value of variable.
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Observer agreement of cross-sectional
measurements
Observer agreement was assessed in 25 random re-selected
CT scans. Distribution of CSA measurements per structure
and observer can be found in Table 4. All measurements made
in the observer analysis correlated signiﬁcantly (P < 0.001).
The total CSA of skeletal muscle at level of C3 had relatively
the best observer agreement, resulting in a signiﬁcant intra-
observer and inter-observer variability of r = 0.99 and
r = 0.98, respectively. The intra-observer and inter-observer
variability per structure was also excellent: paravertebral mus-
cles (intra-observer, r = 0.99; inter-observer, r = 0.98), right
sternocleidomastoid muscle (intra-observer, r = 0.97; inter,
r = 0.93), and left sternocleidomastoid muscle (intra-observer,
r = 0.96; inter-observer, r = 0.96).
Correlation analysis of skeletal muscle mass and
frailty scores
Skeletal muscle mass status, measured in SMI, correlated
best with the G8 score (r = 0.38, P < 0.001), followed by
the GFI score (r = 0.27, P = 0.004). TUG and SMI did not cor-
relate signiﬁcantly with each other (r = 0.11). Scatterplots
for SMI and frailty scores for both G8 and GFI are illustrated
in Figure 3 (A1 and B2, respectively). Data were stratiﬁed
for gender to clarify the effect of gender on the relation be-
tween SMI and frailty scores. Remarkably, G8 showed no dif-
ferences in correlation with SMI between men and women
(r = 0.45, P < 0.001, and P = 0.012, respectively). However,
GFI correlated better to SMI in women (r = 0.35) compared
with men (r = 0.18), but both of these correlations were not
signiﬁcant. Scatterplots, stratiﬁed for gender, with SMI and
frailty scores for both G8 (male, A2; female, A3) and GFI
(male, B2; female, B3) are presented in Figure 3.
Univariate and multivariate logistic regression
Tables 2 and 3 give an overview of the univariate logistic re-
gression analysis with sarcopenia as the dependent variable.
Women (OR 66.1, 95% CI 8.5–512.7), patients with higher
GFI score (OR 1.2, 95% CI 1.0–1.4), high risk of malnutrition
(OR 3.7, 95% CI 1.5–9.2), relatively low BMI (OR 0.8, 95% CI
0.7–0.9), and relatively low G8 score (OR 0.8, 95% CI 0.7–
0.9) were related to sarcopenia. Patients with sarcopenia
tend to have a higher TUG score compared with patients
without sarcopenia, although not statistically signiﬁcant
(median 9.5 vs. 8.0 s, respectively). Of the ﬁve patients with
impaired mobility (TUG ≥20 s), four patients were classiﬁed
with sarcopenia. Sarcopenic patients also tended to have
more moderate to severe comorbidities (42.6% vs. 34.5%),
although also not statistically signiﬁcant.
Body mass index was not included in the multivariate
analysis as we assumed multicollinearity with G8 (variance
inﬂation factor = 2.89; see Table 5 for the multivariate analy-
sis). As all women (except for one) had sarcopenia, the
following variables were considered in the multivariate analy-
ses: G8, GFI, and MUST. The G8 score was found to be an
independent variable associated with sarcopenia (OR 0.76,
95% CI 0.66–0.89, P < 0.001). In other words, a relatively
low G8 score, which corresponds with ‘more’ frailty, was
signiﬁcantly and independently associated with the presence
of sarcopenia.
Univariate and multivariate logistic regression
stratiﬁed by gender
We aimed to analyse men and women separately; however,
analysis for women was not feasible as solely one female
was not sarcopenic. Univariate regression analysis with men
and sarcopenia as dependent variables distinguished age
(OR 1.07, 95% CI 1.01–1.14, P = 0.021), BMI (OR 0.55, 95%
CI 0.41–0.74, P < 0.001), G8 (OR 0.69, 95% CI 0.56–0.84,
P < 0.001), and MUST (P < 0.001) as signiﬁcant variables.
As previously mentioned, we excluded BMI from the analysis
as we assumed multicollinearity with G8. The multivariate
regression analysis for men with sarcopenia as dependent
variable is presented in Table 6. Multivariate logistic regres-
sion analysis in a backward manner isolated G8 as an inde-
pendent variable associated with sarcopenia (OR 0.76, 95%
CI 0.66–0.88, P < 0.001).
Table 4 Observer reliability and reproducibility
Observer A. T. Z. Observer A. H. Inter-observer Intra-observer
Area cm2 Area cm2 R P value R P value
Right sternocleidomastoid muscle 3.68 (±1.12) 3.82 (±1.21) 0.931 <0.001 0.974 <0.001
Left sternocleidomastoid muscle 3.76 (±1.16) 3.63 (±1.06) 0.963 <0.001 0.957 <0.001
Paravertebral muscles 36.90 (±8.54) 37.27 (±9.02) 0.977 <0.001 0.998 <0.001
Total CSA 44.34 (±10.28) 44.73 (±10.73) 0.982 <0.001 0.997 <0.001
CSA, cross-sectional area.
Observer agreement of measured CSA (cm2) at level of C3 in 25 neck computed tomography scans analysed with bivariate Pearson’s r cor-
relation coefﬁcient. The normal distributed data are presented with mean (SD). Underscored P values are signiﬁcant (α < 0.05).
6 A.T. Zwart et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12443
Discussion
In the present study, we investigated the relationship be-
tween sarcopenia and frailty in a large cohort of 112 patients
with primary squamous cell carcinoma of the oropharynx, hy-
popharynx larynx, and oral cavity. This is the ﬁrst study that
conﬁrms that sarcopenia is independently associated with
frailty based on the G8 questionnaire in HNC patients. These
results suggest that screening for sarcopenia on routinely ob-
tained neck CT scans may replace time-consuming frailty
questionnaires in the future.
Previous studies showed that sarcopenia, based on CT
quantitative analysis of skeletal muscle mass, in HNC patients,
is prevalent with occurring in 35.5–54.5% of the HNC pa-
tients.19,27,29 Sarcopenia thus represents an important group
that should be identiﬁed as they are at risk for complications.
Prevalence of sarcopenia in our cohort is 48.2% and thus
in line with previous published prevalence. CT-derived
sarcopenia has been previously related to chemotherapy
dose-limiting toxicity and worsened survival and is aggravated
trough (chemo)radiotherapy in HNC patients.19,27,29,30 How-
ever, despite being a signiﬁcant problem, other associations
Figure 3 Scatterplots for skeletal muscle index and frailty scores. The ﬁgure illustrates the correlation of skeletal muscle index and frailty scores for
both G8 (A) and GFI (B), with corresponding cut-off values for frailty (≤14 and ≥4, respectively). Data of the whole cohort (1) are furthermore stratiﬁed
into men (2) and women (3). The analysis is limited to patients who have completed the G8 (n = 112) and GFI (n = 110) questionnaire. G8, Geriatrics 8;
GFI, Groningen Frailty Index.
Table 5 Multivariate regression analysis for determining if frailty is re-
lated to sarcopenia
OR (95% CI) P value
GFI





G8, Geriatrics 8; GFI, Groningen Frailty Index; MUST, Malnutrition
Universal Screening Tool.
Automatic backwards multivariate logistic regression for several in-
cluded determinants with sarcopenia as dependent variable
(n = 112). Underscored P values are signiﬁcant (α < 0.05).
Table 6 Multivariate regression analysis to assess predictors for
sarcopenia, including only men
OR (95% CI) P value
Age





G8, Geriatrics 8; MUST, Malnutrition Universal Screening Tool.
Automatic backwards multivariate logistic regression for several
included determinants with sarcopenia as dependent variable, in-
cluding only men (n = 82). Underscored P values are signiﬁcant
(α < 0.05).
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of CT-determined sarcopenia in HNC patients are
underreported in literature. To our best knowledge, this is
hence the ﬁrst study that speciﬁcally determined skeletal
muscle mass status with CT image analysis and its association
with frailty in HNC patients. Lack of previous studies is prob-
ably due to the absence of abdominal CT scans in HNC pa-
tients, which are typically used at level of L3 to determinate
the status of skeletal muscle mass. A recent study conﬁrms
this, showing that merely 190 (7%) of the 2840 HNC patients
had an abdominal CT scan.19 The recent published algorithm
of Swartz et al.,18 however, made it assessable to evaluate
the skeletal muscle status from routinely made neck CT scans,
as the CSA of skeletal muscle at C3 strongly correlates with
the CSA of skeletal muscle at L3. Using this method and based
on previously published cut-off, we have determined
sarcopenia using routinely made neck CT scans.
Sarcopenia and frailty are both geriatric syndromes that
partially overlap but essentially differ from each other.31
Frailty is deﬁned as a state where a minor stressor can induce
major implications and is portrayed as loss of function in
physical, psychological, and/or social domains.32 Sarcopenia
represents a state with progressive and generalized loss of
skeletal muscle mass and strength and is therefore more fo-
cused on the physical domain.31 Frailty hence goes further
than the physical factors and incorporates the physiological
and social dimensions as well, including social support and
cognitive function.31 Our expected and demonstrated strong
association between sarcopenia and frailty is also further ex-
plained on the physical domains as we showed that the G8
was related with low skeletal muscle mass, while this was
not demonstrated for the GFI, the latter including social and
more cognitive aspects of frailty. A recent systemic review
showed a higher sensitivity for predicting frailty in the G8
questionnaire than in the GFI that were 87% and 57%, re-
spectively.11 This suggests, G8 is a better questionnaireto rec-
ognize frailty compared to GFI, and thus support our found
association of sarcopenia and frailty basedon G8. Further-
more, patients in our cohort categorized as sarcopenic had
more often an impaired mobility (TUG ≥20 s) compared with
patients without sarcopenia (4 vs. 1, respectively) although
the continuous TUG score was not signiﬁcantly related to
sarcopenia. An impaired mobility as underlying factor for
frailty has been previously conceptualized in the frailty pheno-
type by Fried et al.33 Although others were unable to ﬁnd an
association of sarcopenia (measured as SMI from abdominal
CT scans) with the Carolina Frailty Index in geriatric patients
with different kinds of oncology.34 However, studies using a
physical frailty deﬁnition, with low handgrip strength and
weight loss as part of its criteria, have a tendency to portray
more overlap with sarcopenia.35,36 More accordance with
sarcopenia and frailty is also found when sarcopenia is deter-
mined with reduced handgrip strength and low gait speed, like
the criteria of the European Working Group on Sarcopenia in
Older People. Silver et al. found that the decline in lean body
mass, or skeletal muscle mass, determined with dual-energy
X-ray absorptiometry was associated with signiﬁcant impair-
ment in physical function in patients diagnosed with HNC.37
‘Physical frailty’ and sarcopenia are considered as two com-
mon and largely overlapping conditions38 and support our
demonstrated physical frailty in patients with sarcopenia in
patients with HNC. Furthermore, our demonstrated malnutri-
tion might further explain frailty and sarcopenia in line with
previous research showing such correlation.37,39,40
Our study has several strengths. Firstly, the study was per-
formed in a large group of >100 patients. Secondly, an excel-
lent inter-observer and intra-observer agreements by the two
investigators was demonstrated in the 25 (22%) re-selected
neck CT scans, proving that CSA measurements of skeletal
muscle at level of C3 are both reproducible and reliable.
Thirdly, we applied a strict selection procedure for CT scan
parameters; most included patients had therefore the same
applied CT scan parameters, resulting in relative minimal
differences between the CT scans. Fourthly, a short period
between the diagnosis and quantiﬁcation of skeletal muscle
mass was achieved (1.6 ± 2.4 weeks); thus, alternations in
skeletal muscle due to other external and internal inﬂuences
have been brought to the absolute minimum.
The major limitation of the present study is the lack of
external validation of our ﬁndings. As strong points can be
considered the prospective inclusion of patients and the rela-
tively high participation rate. A limitation of the generalizabil-
ity of the results is the exclusion of patients with inﬁltration
of lymph node metastasis into the sternocleidomastoid
muscle (n = 4). Swartz et al.18 found out that using the
paravertebral muscles and doubling the single not inﬁltrated
sternocleidomastoid muscle was equally predictive for CSA
of skeletal muscle at L3 in comparison with the paravertebral
muscles and both available sternocleidomastoid muscles. This
would have been an option, but in some cases, both
sternocleidomastoid muscles were inﬁltrated, and skeletal
muscle mass analysis was therefore still not feasible (n = 2).
An important note should be made to the cut-off values of
SMI to diagnose sarcopenic patients, as there is no consensus
in the literature that SMI cut-off values should be applied for
categorizing patients with and without sarcopenia. Previous
published cut-off values for SMI are often based on survival
or on lowest quartile,20 but our applied cut-off of SMI
(<43.2 cm2/m2) of Wendrich et al.27 is determined on the
likelihood to develop chemotherapy dose-limiting toxicity.
As the study population of this study is very similar to our
population, we applied this cut-off value. However, we found
that nearly all women were sarcopenic (97%) when applying
the SMI threshold of Wendrich et al.27 The application of this
threshold could be considered as a limitation. Hence, we did
additional analysis with data stratiﬁed for gender. Frailty,
based on G8 questionnaire, was identiﬁed as the only inde-
pendent predictor for sarcopenia, for both the whole cohort
as only men. Furthermore, correlation analysis between SMI
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and G8 frailty score did not differ between men and women,
indicating that the outcome was not gender dependent.
This study showed a clear relationship between sarcopenia
and physical frailty in HNC patients. Further research should
ideally retest our ﬁndings in a second, larger, prospective,
multicentre cohort study. Until our results are veriﬁed in such
larger cohort, the CGA should remain the gold standard to
identify frailty. Sarcopenia, as a biomarker in HNC patients
has the potential to predict clinical outcome, treatment re-
sponse, toxicity, post-operative morbidity, and survival.
Therefore, screening for sarcopenia would allow better
selection of patients for intensive therapy, although further
research is needed before this can be implemented. Further
research should also test the predictive value of skeletal mus-
cle mass regarding adverse clinical outcome in comparison
with the current gold standard, the CGA. In addition to our
quantitative analysis of skeletal muscle, qualitative research
with muscle radio-density should be performed to analyse
its predictive value to frailty in the head and neck cohort.
As recently, muscle density on CT imaging was reported to
be more associated with the Carolina Frailty Index in older
adults with cancer than muscle mass.34 However, such an
analysis was not possible in our study, as included patients
underwent contrast enhanced CT scans, which is not reliable
for muscle density measurements.41 Furthermore, the predic-
tive value of C3 measured skeletal muscle mass to identify
frailty should be compared with L3measured skeletal muscle.
However, in our cohort, only a couple of patients had CT
scans of both the neck and abdomen; therefore, this analysis
was not feasible. Validation of skeletal muscle mass assess-
ment on MRI and low dose CT neck scans would be of inter-
est to ensure that all HNC patients can be screened for
sarcopenia before, during, and after treatment.
Conclusions
We isolated a signiﬁcant, independent relationship between
the presence of sarcopenia, derived from neck CT image anal-
ysis, and frailty based on the G8 questionnaire in 112 HNC pa-
tients. Screening for sarcopenia using the CT-derived skeletal
muscle mass measurement potentially could replace time-
consuming frailty questionnaires; however, until this CGA
has to remain the gold standard. Screening for sarcopenia
could help to select the (un)suitable patients for therapy,
which is highly clinically relevant. Furthermore, skeletal mus-
cle mass status has the potential to be a cost-effective, non-
invasive biomarker.
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